SCLXWScilex Holding Company Warrant
0.1051USD-34.15%Mkt Cap: —P/E: —3d ago
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical syst…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)33.86M $
Gross Profit19.65M $
Net Income (TTM)-358.73M $
Revenue/Share3.432 USD
Last Price0.1051 USD
Fiscal Year End—
MR Quarter—
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.01
EPS (TTM)—
EPS (Forward)—
52W Range
0.10510% of range0.2100
52W High0.2100 USD
52W Low0.1051 USD
Profitability
Gross Margin64.97%
Oper. Margin-373.49%
EBITDA Margin0.00%
Profit Margin-1185.78%
ROE172.65%
ROA-98.29%
Growth
Revenue Growth72.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF3.82M $
CapEx (TTM)733.00K $
FCF Margin17.68%
FCF Yield—
Net Debt103.00M $
Net Debt/EBITDA-0.38
Balance Sheet
Debt/Equity-0.60
Current Ratio0.08
Quick Ratio0.07
Book Value/Sh-29.5440 USD
Cash/Share0.4780 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float5.69M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta1.74
S&P 52W Chg18.16%
Avg Vol (30d)724
Avg Vol (10d)—
Technical Indicators
RSI (14)35.9
MACD0.0065
MACD Signal0.0079
MACD Hist.-0.0014
BB Upper0.2055 USD
BB Middle0.1495 USD
BB Lower0.0935 USD
BB Width74.93%
ATR (14)0.0152 USD
Vol Ratio (20d)0.24x